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In this study, the hsp60 and hsp70 heat shock protein antigens of Mycobacterium tuberculosis were tested as
potential vaccine candidates, using purified recombinant protein antigens or antigens encoded in the form of
a DNA plasmid vaccine. Guinea pigs vaccinated with a mixture of the two proteins showed no evidence of
resistance to low-dose aerosol challenge infection and quickly developed severe lung damage characterized by
necrotizing bronchointerstitial pneumonia and bronchiolitis. As a result, we turned instead to a DNA vacci-
nation approach using a plasmid encoding the hsp60 antigen of M. tuberculosis. Although immunogenic in mice,
vaccination with plasmid DNA encoding hsp60 was not protective in that model or in the guinea pig model and
again gave rise to similar severe lung damage. This study seriously questions the safety of vaccines against
tuberculosis that target highly conserved heat shock proteins.
When cultures of Mycobacterium tuberculosis are exposed to
stress, notably an increase in temperature, they begin to syn-
thesize an extensive family of chaperonin-like proteins which
are collectively referred to as the heat shock proteins of the
organism (12, 18, 19, 25–27). Under normal physiological con-
ditions, however, only a few of these proteins can be detected;
these include DnaK protein (hsp70) and the GroES protein
(hsp10), which are well represented, and the GroEL 65-kDa
protein (hsp60), which is found in only trace amounts (21).
Both the hsp70 and hsp60 molecules have recently been
shown to have significant promise as vaccines against tubercu-
losis. Culture filtrates dominated by hsp70 (16) or purified
hsp70 (6), when delivered in a powerful adjuvant, induce high
levels of protection in the sensitive guinea pig challenge model.
The hsp60 molecule, when delivered encoded in the form of a
DNA vaccine, induces immunity that not only protects against
subsequent challenge (13, 23) but also is capable of inducing
sterilizing immunity when given as a postexposure vaccine (14).
We have recently reported (1, 15) that culture filtrate pro-
teins of M. tuberculosis delivered in a relatively mild adjuvant
and supplemented with the cytokine interleukin-2 (IL-2) do
not have a direct effect on the lung bacterial load following a
challenge infection in the guinea pig model but do appear to
induce a lymphocytic response in the lungs that prevents the
caseous necrosis that would otherwise develop. Given this in-
formation, we hypothesized that a mixture of hsp60 and hsp70
proteins should have a similar effect, perhaps with an element
of direct protection given the previous results of others, in our
model. However, no protection was observed, and the animals
immunized with these proteins rapidly developed a necrotizing
bronchointerstitial pneumonia and bronchiolitis after aerosol
challenge.
Because of this negative result, we turned to the tactic of
DNA vaccination, using hsp60 as an example, given previous
reports of the very high effectiveness of this approach (13, 14).
Here again, no protection was observed in either the mouse or
guinea pig model despite direct evidence that the DNA was
highly immunogenic. Histological analysis revealed a similar
spectrum of moderate to severe, multifocal to disseminated
necrotizing bronchointerstitial pneumonia with bronchiolitis.
MATERIALS AND METHODS
Animals. Specific-pathogen-free 6- to 8-week-old female C57BL/6 mice and
female outbred Hartley guinea pigs were purchased from Charles River Labo-
ratories (North Wilmington, Mass.) and held under barrier conditions in a level
III biohazard laboratory. (C57BL/6 3 BALB/c)F1 female mice were bred in the
animal facilities at the Pasteur Institute, Brussels, Belgium. Guinea pigs weighed
approximately 500 to 600 g at the beginning of the experiment and were housed
two to a cage. All animals had free access to water and standard mouse or guinea
pig chow.
Bacterial infections. M. tuberculosis Erdman and H37Rv and Mycobacterium
bovis BCG Pasteur and Copenhagen were grown to early mid-log phase in
Proskauer Beck medium containing 0.02% Tween 80. Cultures were aliquoted
into 1-ml tubes and stored at 270°C until used. Thawed aliquots were diluted in
double-distilled sterile water to the desired inoculum concentrations. An aerosol
generation device (Glas-Col, Terre Haute, Ind.) was used to expose the animals
to an aerosol of M. tuberculosis and was calibrated to deliver approximately 20
bacilli into each guinea pig lung. Mice were infected in a similar manner with
approximately 50 to 100 bacilli. In some experiments, mice were challenged
intranasally with 2 3 104 CFU of M. tuberculosis H37Rv. The numbers of viable
bacteria in target organs were determined at various time points by plating serial
dilutions of whole organ homogenates on nutrient Middlebrook 7H11 agar and
counting bacterial colonies after 20 days of incubation at 37°C. Data were
expressed as the log10 of the mean number of bacteria recovered per organ.
Protein vaccine. Recombinant M. bovis hsp60 and M. tuberculosis hsp70 were
kindly provided from the World Health Organization repository by M. Singh
(Braunschweig, Germany). Guinea pigs were immunized subcutaneously with a
mixture of the two heat shock proteins (20 mg each) emulsified into an adjuvant
vehicle (100 mg of monophosphoryl lipid A [MPL] [Ribi ImmunoChem Re-
search, Hamilton, Mont.] solubilized in triethanolamine by sonication; stock
solutions contained 0.02% triethanolamine and 0.4% dextrose) and supple-
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mented with 20 mg of Proleukin-polyethylene glycol IL-2 (Chiron, Emeryville,
Calif.). Animals were given the vaccine twice 3 weeks apart and then challenged
4 weeks later by aerosol exposure. As a positive control, animals were injected
intradermally with BCG Copenhagen (103 bacilli/guinea pig) a single time, cor-
responding to the second set of injections.
DNA vaccines. DNA vaccines encoding the hsp60 and Ag85A protein antigens
of M. tuberculosis were constructed as previously described (7, 9) using the
plasmid vector V1Jns-tPA. To verify immunogenicity, mice were injected three
times at 3-week intervals with 100 mg of plasmid DNA encoding Ag85A or hsp60.
Three weeks after the last immunization, spleens from five mice were analyzed
individually for IL-2 and gamma interferon (IFN-g) secretion in response to the
specific antigens purified from M. bovis BCG culture filtrate (4, 5, 8) or to the
polyclonal mitogen pokeweed mitogen (PWM).
Two months after the last DNA vaccination, mice were challenged by intra-
nasal inoculation with M. tuberculosis H37Rv, and the bacterial load in the lungs
was determined 1 month later as described above.
Guinea pigs were vaccinated using a biojector device (Bioject, Portland, Oreg.)
three times at 3-week intervals. Each guinea pig was given 200 mg of plasmid
DNA in saline into each hind quadriceps muscle (400 mg total per immuniza-
tion). Positive control animals received BCG as described above. One month
later all animals were given a low-dose aerosol challenge as described above.
Lungs from one set of animals were harvested 30 days later to determine lung
bacterial counts, while a second group were left to determine survival times.
These animals were weighed regularly, and a 10% loss of body weight was used
as a criterion for euthanasia.
Cytokine production. DNA-vaccinated mice were sacrificed 3 weeks after the
third DNA vaccination, and spleens were removed aseptically. Spleens from five
mice were analyzed individually in each group. Spleen cells were adjusted to a
concentration of 4 3 106 cells/ml and grown in round-bottomed microwell plates
(Nunc) in RPMI 1640 medium (Gibco-BRL) supplemented with glutamine,
HEPES, 50 mM 2-mercaptoethanol, antibiotics, and 10% heat-inactived fetal
calf serum (Gibco-BRL). A volume of 180 ml of cell suspension was added to 20
ml of purified Ag85A or hsp60 (final concentration, 5 mg/ml) or PWM (dilution
of 1:50 from a stock solution). Cells were incubated at 37°C in a humidified CO2
incubator, and supernatants were harvested after 24 h (IL-2) and 72 h (IFN-g).
Supernatants from three separate wells were pooled and stored frozen at 220°C
until assay.
IL-2 activity was measured using a bioassay. Briefly, a volume of 100 ml of 24-h
culture supernatant was added to 100 ml of CTLL-2 cells (105/ml) and incubated
for 48 h. [3H]thymidine (Amersham) (8.3 Ci/ml) was added (0.4 mCi/well) during
the last 6 h of culture. Cells were harvested on a Titertek cell harvester, and the
radioactivity recovered on the fiber mats was counted in a Betaplate scintillation
counter. Each sample was tested in duplicate. IL-2 levels are expressed as mean
counts per minute, and the standard deviation was below 10%. In this assay,
10.000 cpm corresponded to 3.12 IU/ml or about 600 pg/ml, and the detection
limit was around 10 pg/ml.
IFN-g production was quantified in duplicate using a cytopathic effect reduc-
tion assay on mouse L929 fibroblastoid cells with vesicular stomatitis virus as the
challenge virus on 72-h culture supernatants. Titers are expressed as mean log2
values obtained for five individual mice. The value of log2 5 1 corresponds to 110
pg/ml as measured in the Genzyme mouse IFN-g DuoSet (catalog no. 80-3931-
00). The detection limit of the bioassay is about 75 pg/ml.
Histological analysis. Tissues were fixed in 10% neutral buffered formalin for
routine microscopic processing. All tissues were stained with hematoxylin and
eosin. In each case, the left caudal lung lobe was sagittally sectioned through the
middle of the lobe. The tissues were coded and evaluated by a veterinary pa-
thologist without prior knowledge of time or treatment group. Some lesion
variability within vaccination groups was noted, presumably due to the use of
outbred animals; however, this variability was much less pronounced than lesion
variability between vaccine groups.
RESULTS
Vaccination of guinea pigs with the heat shock protein mix-
ture. Guinea pigs were vaccinated with a mixture of hsp60 and
hsp70 in MPL adjuvant containing a long-lived form of IL-2,
using a vaccination protocol previously shown (1) to be effica-
FIG. 1. Vaccination of guinea pigs with an hsp60-hsp70 protein vaccine mixture. (A) Bacterial load in lungs 30 days after aerosol challenge. (B) Mean survival. Note
that none of the BCG-vaccinated animals had died when the experiment was stopped at 27 weeks. (C) Mean weight gain. For panels A to C, n 5 4 and error bars
indicate standard errors of the means. (D) Weight loss of individual animals. Open squares, adjuvant controls; closed squares, hsp60-hsp70-vaccinated animals.











cious for other mycobacterial proteins. Thirty days after aero-
sol challenge, animals were euthanized and bacterial loads
were determined. Guinea pigs given the hsp60-hsp70 mixture
had lung bacterial numbers similar to those in animals receiv-
ing the adjuvant–IL-2 negative control inoculum (Fig. 1A). In
contrast, guinea pigs receiving BCG had a lung load reduction
of 2 log10 units. This was also reflected in similar survival times
for guinea pigs given the hsp60-hsp70 vaccine and the adjuvant
control group (Fig. 1B), as well as weight gain or loss (Fig. 1C)
and the kinetics of this loss (Fig. 1D).
Evidence for severe lung damage in guinea pigs vaccinated
with the protein vaccine. In our previous experience with other
vaccine candidates, prevention or delay of lung necrosis could
be achieved using proteins delivered in the MPL–IL-2 vehicle
(1). In the present case, however, the reverse result was ob-
tained, with animals immunized with hsp60-hsp70 showing ev-
idence of severe lung damage. As shown in Fig. 2, vaccinated
guinea pigs developed severe pneumonia with airway damage
characterized by multifocal erosions and/or complete loss of
bronchiolar epithelium and exposure of the underlying base-
ment membrane. A direct physical connection between peri-
bronchiolar inflammation and the airway lumen was often ob-
served. Such lumens were filled with necrotic cellular debris,
polymorphonuclear leukocytes (neutrophils), mucus, and ex-
foliated epithelial cells. Epithelial hyperplasia (repair) was of-
ten observed at the margins of these denuded areas of epithe-
lium.
DNA vaccine constructs were highly immunogenic. Given
the failure of the protein vaccine approach, we then used the
tactic of generating a DNA vaccine against the hsp60 molecule,
given recent success with this approach (1, 9, 13, 14). To es-
tablish the immunogenicity of the plasmid DNA encoding
hsp60, mice were immunized with this material and tested for
antigen-specific spleen cell IL-2 and IFN-g secretion in vitro. A
construct made in an identical manner but encoding the
Ag85A molecule of M. tuberculosis was used for comparison. It
was found (Table 1) that vaccination with both plasmids in-
duced significant levels of IL-2 and IFN-g from immune spleen
cells.
DNA vaccination in the mouse model. By a protocol that has
previously shown that DNA vaccination of mice with a plasmid
encoding the Ag85 antigen is protective against aerosol chal-
lenge, mice were immunized with either the hsp60 DNA vac-
cine or Ag85. Protective activity 30 days after intranasal chal-
lenge was observed in mice receiving the Ag85 DNA vaccine,
but no reduction in the lung bacterial load was observed in
mice immunized with the hsp60 DNA vaccine (Table 2).
The DNA vaccine encoding hsp60 was not protective in
guinea pigs. After vaccination with the hsp60 DNA plasmid,
guinea pigs were challenged by aerosol, and the bacterial load
in the lungs was determined 1 month later. No protection was
seen in these animals compared to controls (Table 3).
Evidence for severe pathology in vaccinated guinea pigs. In
guinea pigs vaccinated with BCG, a mild diffuse interstitial
FIG. 2. Representative photomicrographs of a lung from a guinea pig vaccinated with the hsp60-hsp70 protein mixture. (A) Terminal bronchiole surrounded by
granulomatous-lymphocytic inflammation. The lumen is filled with mucus, sloughed epithelium, and necrosuppurative cellular debris. Magnification, 3160. (B)
Terminal bronchiole with focal epithelial ulceration (arrowhead) and focal epithelial hyperplasia (arrow). The lumen is again filled with mucus, sloughed epithelium,
and necrosuppurative cellular debris. Magnification, 3320. Hematoxylin and eosin staining was used.
TABLE 1. Cytokine secretion by T cells from mice given DNA vaccinesa
Stimulating antigen
IL-2 (cpm) IFN (log2)
Ag85A plasmid hsp60 plasmid Ag85A plasmid hsp60 plasmid
Control 310 6 94 288 6 88 0.92 6 0.62 0.85 6 0.48
Ag85A 10,222 6 3,550 NDb 5.87 6 1.14 ND
hsp60 ND 5,235 6 3,602 ND 4.48 6 0.78
PWM 20,630 6 2,482 23,512 6 4,471 7.57 6 0.65 7.14 6 0.44
a n 5 5 mice per assay.
b ND, not determined.











pneumonia with alveolar walls variably thickened by lympho-
cytes was observed in the lungs of these animals 30 days after
aerosol challenge. For animals vaccinated with hsp60 DNA,
about half of the animals exhibited a moderate to severe,
multifocal to coalescing, granulomatous interstitial pneumonia
with scattered aggregates of lymphocytes, whereas the other
animals presented with a necrotizing granulomatous bron-
chointerstitial pneumonia (Fig. 3). All negative control animals
given the empty plasmid showed the latter type of pathology.
Additionally, within the hsp60 DNA-vaccinated group, bron-
chiolar epithelial erosion and/or complete ulceration similar to
that seen in the guinea pigs vaccinated with the hsp60-hsp70
protein mixture was also observed. The bronchiolar lumens of
the DNA-vaccinated animals were packed with polymorpho-
nuclear leukocytes, mucus, sloughed epithelium, and necrotic
cellular debris.
DISCUSSION
In this study, we examined the efficacy of two potential heat
shock protein-based tuberculosis vaccine candidates. Neither
the protein- nor the DNA-based vaccines had any protective
effect, measured as a reduction in bacterial loads after M.
tuberculosis challenge infections. In addition, the lung pathol-
ogy in guinea pigs vaccinated with either of these candidates
ranged from a moderate to severe necrotizing granulomatous
bronchointerstitial pneumonia with bronchiolitis.
The finding of severe airway damage and complete lack of
protection in guinea pigs vaccinated with a preparation con-
taining hsp70 is in complete contrast to earlier work with this
protein, in which the animals were significantly protected by
this material delivered in a potent adjuvant vehicle. In our
study, however, a much milder adjuvant formulation was used,
which consistently has minimal influence on bacterial load in
the guinea pig model but does tend to prevent adverse lung
pathology and give rise to substantial long-term survival.
Hence, the severe pathology seen in guinea pigs immunized
with hsp70 in the MPL adjuvant is paradoxical and seems to
imply that the protein induces immunity that is effective only
just directly after the challenge infection is given, and then only
if a much stronger adjuvant is used.
Because of these findings, we turned to the DNA vaccination
approach, and further experiments were performed using a
plasmid DNA vaccine encoding hsp60 of M. tuberculosis. Initial
experiments with mice showed that the DNA was highly im-
munogenic, but subsequent experiments in which these ani-
mals were then challenged with M. tuberculosis did not indicate
any protective effect for the hsp60-encoding plasmid. In con-
trast, vaccination with plasmid DNA encoding Ag85A signifi-
cantly reduced the lung bacterial load compared to that in mice
vaccinated with empty plasmid vector, confirming previous re-
sults using either aerosol or intravenous M. tuberculosis chal-
FIG. 3. Lung pathology after DNA vaccination and aerosol challenge. (A)
Plasmid vector control. Severe extensive granulomatous interstitial pneumonia
with centralized area of necrosis (arrow) is seen. Magnification, 3160. (B)
Guinea pig vaccinated with hsp60 plasmid DNA. Severe extensive granuloma-
tous bronchointerstitial pneumonia with polymorphonuclear leukocytes, mucus,
sloughed epithelium, and necrotic cellular debris filling the airway lumen is
shown. Magnification, 3160. (C) High magnification of airway in panel B. Note
transepithelial migration of polymorphonuclear cells and epithelial erosion (ar-
rowhead) and epithelial hyperplasia (arrow). Magnification, 3310. Hematoxylin
and eosin staining was used.
TABLE 2. Protection of mice after vaccination
Vaccine Lung bacterial load(log10)a
Protection
(log10)
Control DNA 4.87 6 0.37
BCG 3.96 6 0.38 0.91
Ag85A DNA 4.34 6 0.18 0.53
hsp60 DNA 5.17 6 0.24 None
a Measured 30 days after intranasal challenge with M. tuberculosis H37Rv.
TABLE 3. Protection of guinea pigs after DNA vaccination
Vaccine
Bacterial load (log10)a in:
Lungs Spleen
Control DNA 5.01 6 0.21 5.19 6 0.31
BCG 4.10 6 0.31 1.78 6 1.75
hsp60 DNA 5.11 6 0.22 5.93 6 0.35
a Thirty days after low-dose aerosol exposure to M. tuberculosis H37Rv.











lenge (1, 9, 10). A similar outcome was seen in guinea pigs
vaccinated using a highly effective biojector protocol, in which
no reduction in lung bacterial load was observed and there was
no evidence of any survival beyond that for negative control
animals. Moreover, histological analysis of the lungs of these
guinea pigs revealed a similar spectrum of necrotizing bron-
chointerstitial granulomatous pneumonia and bronchiolitis.
A number of DNA vaccine candidates have been shown to
have activity in small animal models of tuberculosis (1, 7, 9, 10,
13–15, 22, 23, 28). For example, a DNA vaccine containing the
M. tuberculosis gene encoding Ag85A (mycolyl transferase)
had a protective effect in mice challenged by aerosol infection
(1, 9). In guinea pigs challenged similarly, no significant effect
on the lung bacterial load was initially observed, but these
animals exhibited excellent long-term survival with the devel-
opment of lymphocytic granulomas and no evidence of lung
tissue necrosis (1). Other targets include ESAT-6, PstS-1, and
PstS-3 (7, 10, 22, 28).
A very promising candidate, a DNA vaccine made from the
hsp60 gene of Mycobacterium leprae, has been shown to dra-
matically reduce bacterial loads in mice infected intravenously
when given both prior to (2, 13, 23) and after (14) the M.
tuberculosis challenge. Moreover, in a Cornell-type model,
therapeutic administration of the vaccine resulted in sterilizing
immunity in some animals (14), although we should note here
that the bacterial loads recovered in that study from steroid-
treated infected control mice after prolonged isoniazid and
pyrazinamide therapy seemed to us to be extraordinarily high
given our own experience (3) and that of others (17). More-
over, in contrast to those results, we have completely failed to
see any postexposure effects using two vaccines (a culture fil-
trate-based vaccine and the Ag85 DNA vaccine) shown previ-
ously to be effective if given prior to challenge (24).
We cannot offer an explanation here as to why our hsp60
DNA vaccine had no effect. It was engineered from the M.
tuberculosis hsp60 gene (rather than M. leprae), stimulated
substantial cytokine responses from T cells from immunized
mice, and was inoculated into guinea pigs using a highly effi-
cient biojector protocol. Perhaps much more troubling than
the lack of protection, however, was the observation of severe
pulmonary pathology in these vaccination approaches, which
questions the safety of the hsp60 vaccine candidates. We do
not know the etiology of the pathological process in these
guinea pigs, but an obvious starting point would be the poten-
tial induction of autoimmunity given the highly conserved na-
ture of this molecule in mycobacteria and mammals (11, 20,
26). In addition, moreover, there were certain similarities in
the pathology in these animals to the broad clinical syndrome
referred to as asthma, allergic bronchitis, or allergic pneumo-
nia, which has been recognized in many mammalian species. In
this syndrome, a prominent infiltration of eosinophils into an
edematous, hyperemic bronchial lamina propria is classically
seen, and airway lumens fill with a mix of mucus, sloughed
epithelial cells and many eosinophils. Some of these features
were observed within the guinea pigs tested in the present
study, thus suggesting a form of an allergic phenomenon, al-
though whether this is indeed the basis remains unproven.
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